Thermo Fisher Reports Strong Q4 and Full Year 2025 Results, Driven by Revenue and EPS Growth
Summary
Thermo Fisher Scientific announced strong fourth quarter and full year 2025 financial results, with notable growth in revenue and EPS, supported by strategic capital deployment and innovation.
Key Events
-
Strong Fourth Quarter Performance
Fourth quarter 2025 revenue grew 7% to $12.21 billion, with GAAP diluted EPS increasing 9% to $5.21 and adjusted EPS growing 8% to $6.57.
-
Solid Full Year 2025 Results
Full year 2025 revenue increased 4% to $44.56 billion, while GAAP diluted EPS grew 7% to $17.74 and adjusted EPS rose 5% to $22.87.
-
Significant Capital Deployment
The company deployed approximately $16.5 billion in 2025, including $13 billion for M&A, completing acquisitions like Solventum's Filtration and Separation business and Sanofi's Ridgefield site, and announcing the acquisition of Clario. Additionally, $3.6 billion was returned to shareholders through buybacks and dividends.
-
Strategic Growth Initiatives
Thermo Fisher advanced its growth strategy through new product launches, including the Thermo Scientific Orbitrap Astral Zoom mass spectrometer, and established strategic collaborations with OpenAI and the Chan Zuckerberg Institute for Advanced Biological Imaging.
Analysis
Thermo Fisher Scientific delivered robust financial results for both the fourth quarter and full year 2025, demonstrating consistent growth in revenue and earnings per share. The company's strategic execution, including significant capital deployment for M&A and shareholder returns, alongside innovative product launches and key collaborations, underpins its strong market position. These results reinforce the company's positive trajectory and operational efficiency, providing a solid foundation as it enters 2026.
At the time of this filing, TMO was trading at $614.41 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $228.4B. The 52-week trading range was $385.46 to $643.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.